EX-99.1 2 ex_627209.htm EXHIBIT 99.1 ex_627209.htm

Exhibit 99.1

 

ReposiTrak Increases Net Income and Earnings Per Share 17%

on 8% Revenue Growth in Fiscal 2024 Second Quarter

 

Company Accelerates Onboarding Hundreds of Traceability Customers

 

Salt Lake City, UT February 14, 2024 –ReposiTrak (NYSE: TRAK), the world's largest food traceability and regulatory compliance network, built upon its proven inventory management and out-of-stock reduction SaaS platform, today announced financial results for the second fiscal quarter (“FQ2 2024”) ended December 31, 2023.

 

Second Quarter Financial Highlights:

 

 

Second quarter total revenue increased 8% to $5.13 million from $4.75 million.

 

Recurring revenue increased 8%, net of the planned elimination of high-touch, low-opportunity revenue, to $5.13 million from $4.74 million, representing approximately 99% of total revenue.

 

Quarterly operating expense increased 9% to $3.88 million from $3.57 million, representing investments in sales, marketing and onboarding costs to further increase awareness about the FDA mandate and accelerating onboarding of customers to the ReposiTrak Traceability Network (“RTN”) solution.

 

Quarterly operating income increased 5% to $1.24 million from $1.18 million last year in spite of higher costs to gear up for traceability.

 

Quarterly GAAP net income increased 15% to $1.45 million from $1.27 million last year.

 

Quarterly net income to common shareholders was $1.30 million, up 17% from $1.12 million last year.

 

Quarterly EPS of $0.07, up 17% from $0.06 last year.

 

During the quarter, the Company repurchased 22,012 common shares at an average price of $8.79 per share for a total of $193,492.

 

During the quarter, the Company repurchased 70,093 preferred shares for the stated redemption price of $10.70 per share for a total of $749,995.

 

During the quarter, the Board of Directors approved an increase in the Company’s quarterly cash dividend, to 6.6 cents per share annually (1.65 cents per share quarterly), commencing with the December 2023 dividend.

 

Randall K. Fields, Chairman and CEO of ReposiTrak, commented, “ReposiTrak some years ago identified traceability as an important add-on and direction for our business. We positioned ourselves to be the market leader, and that is coming true. We are delivering traceability solutions, and the adoption of the repository traceability network has exceeded our early expectations. Based on recent market developments, we are convinced that the total addressable market is expanding significantly beyond our initial estimates. Traceability is already contributing to our top and bottom lines, and we expect that to increase significantly over the next two to three years.”

 

Mr. Fields continued, “In our view, even before the FDA mandate deadline of 2026, we expect the RTN will have significantly expanded to include a substantial portion of the food industry, creating another robust moat around our business for years to come. We believe a number of large retailers and wholesalers are in the process of accelerating the FDA deadline and scope. We are well prepared to take advantage of these changes. We are meeting this opportunity from a position of strength, with solid growth, consistent profitability and more than $23 million in cash on our balance sheet.”

 

Second Fiscal Quarter Financial Results (three months ended December 31, 2023, vs. three months ended December 31, 2022):

 

Total revenue was up 8% to $5.13 million as compared to $4.75 million in the prior-year second quarter. Total operating expense was $3.88 million, up 9% compared to $3.57 million last year. General and administrative expense increased by 8%. GAAP net income was $1.45 million compared to $1.27 million. Net income to common shareholders was $1.30 million, or $0.07 per diluted share, compared to $1.12 million, or $0.06 per diluted share.

 

 

 

Year-to-Date Financial Results (six months ended December 31, 2023, vs. six months ended December 31, 2022):

 

Total revenue was up 8% to $10.19 million as compared to $9.47 million in the prior-year period. Total operating expense was $7.75 million, up 10% compared to $7.07 million last year. GAAP net income was $2.83 million compared to $2.55 million. Net income to common shareholders was $2.54 million, or $0.14 per basic share and diluted share, compared to $2.26 million, or $0.12 per basic and diluted share.

 

Return of Capital:

 

In the second quarter of fiscal 2024, the Company repurchased 22,012 common shares at an average price of $8.79 per share for a total of $193,492. Since inception, the Company has repurchased approximately 2.12 million shares of common stock at an average price of $6.13 per share, for a total of approximately $13 million. The Company has approximately $8 million remaining on the $21 million total buyback authorization since inception.

 

In the second quarter of fiscal 2024, the Company repurchased 70,093 preferred shares at the stated redemption price of $10.70 per share for a total of $749,995. The amount remaining under our repurchase program is $8.21 million. As previously announced, the Company anticipates redeeming all of its preferred stock issued and outstanding over the next three years from August 29, 2023.

 

In September 2022, the Company’s Board of Directors declared a quarterly cash dividend of $0.015 per share ($0.06 per year). In November 2023, the Board of Directors approved a 10% increase in the quarterly cash dividend, to 6.6 cents per share annually, or 1.65 cents per share quarterly, commencing with the December 2023 dividend.

 

Balance Sheet:

 

The Company had $23.25 million in cash and cash equivalents at December 31, 2023, compared to $23.99 million at June 30, 2023. The reduction in cash reflects the payment of common stock dividends, and buyback of common shares and redemption of preferred stock during the period. The Company had nothing drawn on its working line of credit as of December 31, 2023 or June 30, 2023.

 

Conference Call:

 

The Company will host a conference call at 4:15 p.m. Eastern today to discuss the Company’s results. The conference call will also be webcast and will be available via the investor relations section of the Company’s website, www.parkcitygroup.com.

 

Participant Dial-In Numbers:

Date: Wednesday, February 14, 2024

Time: 4:15 p.m. ET (1:15 p.m. PT)

Toll-Free: 1-877-407-9716

Toll/International 1-201-493-6779

Conference ID: 13744233

 

Replay Dial-In Numbers:

Toll Free: 1-844-512-2921

Toll/International: 1-412-317-6671

Replay Start: Wednesday, February 14, 2024, 7:15 p.m. ET

Replay Expiry: Thursday, March 14, 2024 at 11:59 p.m. ET

Replay PIN Number: 13744233

 

 

 

About ReposiTrak

 

ReposiTrak (NYSE:TRAK), formerly Park City Group, provides retailers, suppliers and wholesalers with a robust solution suite to help reduce risk and remain in compliance with regulatory requirements, enhance operational controls and increase sales with unrivaled brand protection. Consisting of three product families – food traceability, compliance and risk management and supply chain solutions – ReposiTrak’s integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, visit https://repositrak.com

 

Forward-Looking Statement

 

Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “if”, “should” and “will” and similar expressions as they relate to Park City Group, Inc., Park City Group d/b/a ReposiTrak, or ReposiTrak (“Park City Group”) are intended to identify such forward-looking statements. Park City Group may from time-to-time update these publicly announced projections, but it is not obligated to do so. Any projections of future results of operations should not be construed in any manner as a guarantee that such results will in fact occur. These projections are subject to change and could differ materially from final reported results. For a discussion of such risks and uncertainties, see “Risk Factors” in Park City Group annual report on Form 10-K, its quarterly report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

 

Investor Relations Contact:

 

John Merrill, CFO

Investor-relations@repositrak.com

 

Or

 

FNK IR

Rob Fink

646.809.4048

rob@fnkir.com

 

 

 

 

REPOSITRAK, INC.

Consolidated Condensed Balance Sheets (Unaudited)

 

   

December 31,

2023

   

June 30,

2023

 

Assets

               

Current Assets

               

Cash and cash equivalents

  $ 23,253,071     $ 23,990,879  

Receivables, net of allowance for doubtful accounts of $219,163 and $170,103 at December 31, 2023 and June 30, 2023, respectively

    3,799,551       2,523,019  

Contract asset – unbilled current portion

    150,180       186,959  

Prepaid expense and other current assets

    366,766       573,763  

Total Current Assets

    27,569,568       27,274,620  
                 

Property and equipment, net

    716,979       986,300  
                 

Other Assets:

               

Deposits and other assets

    22,414       22,414  

Prepaid expense – less current portion

    8,996       36,282  

Contract asset – unbilled long-term portion

    108,052       108,052  

Operating lease – right-of-use asset

    280,958       310,796  

Customer relationships

    197,100       262,800  

Goodwill

    20,883,886       20,883,886  

Capitalized software costs, net

    541,450       698,281  

Total Other Assets

    22,042,856       22,322,511  
                 

Total Assets

  $ 50,329,403     $ 50,583,431  
                 

Liabilities and Shareholders Equity

               

Current liabilities

               

Accounts payable

  $ 332,306     $ 431,387  

Accrued liabilities

    1,634,620       1,620,000  

Contract liability – deferred revenue

    2,026,565       1,903,001  

Operating lease liability – current

    61,372       58,771  

Notes payable and financing leases – current

    216,542       219,262  

Total current liabilities

    4,271,405       4,232,421  
                 

Long-term liabilities

               

Operating lease liability – less current portion

    231,830       263,047  

Notes payable and financing leases – less current portion

    83,677       206,032  

Total liabilities

    4,586,912       4,701,500  
                 

Commitments and contingencies

               
                 

Stockholders equity:

               

Preferred Stock; $0.01 par value, 30,000,000 shares authorized;

               

Series B Preferred, 700,000 shares authorized; 625,375 shares issued and outstanding at December 31, 2023 and June 30, 2023;

    6,254       6,254  

Series B-1 Preferred, 550,000 shares authorized; 142,309 and 212,402 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively

    1,423       2,124  

Common Stock, $0.01 par value, 50,000,000 shares authorized; 18,158,730 and 18,309,051 issued and outstanding at December 31, 2023 and June 30, 2023, respectively

    181,590       183,093  

Additional paid-in capital

    65,637,265       67,732,887  

Accumulated other comprehensive loss

    (5,904 )     -  

Accumulated deficit

    (20,078,137 )     (22,042,427 )

Total stockholders equity

    45,742,491       45,881,931  

Total liabilities and stockholders equity

  $ 50,329,403     $ 50,583,431  

 

 

 

 

REPOSITRAK, INC.

Consolidated Condensed Statements of Operations and Comprehensive Income (Unaudited)

 

   

Three Months Ended

December 31,

   

Six Months Ended

December 31,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Revenue

  $ 5,125,751     $ 4,750,513     $ 10,185,863     $ 9,470,990  
                                 

Operating expense:

                               

Cost of revenue and product support

    973,287       866,642       1,739,621       1,699,346  

Sales and marketing

    1,264,377       1,226,812       2,769,878       2,427,071  

General and administrative

    1,347,278       1,252,357       2,626,601       2,475,819  

Depreciation and amortization

    299,958       229,160       608,903       465,166  

Total operating expense

    3,884,900       3,574,971       7,745,003       7,067,402  
                                 

Income from operations

    1,240,851       1,175,542       2,440,860       2,403,588  
                                 

Other income (expense):

                               

Interest income

    316,445       199,266       574,606       278,358  

Interest expense

    (7,576 )     (18,058 )     (13,920 )     (42,710 )

Unrealized gain (loss) on short term investments

    15,456       (31,406 )     42,642       (38,821 )

Other gain

    -       -       -       70,047  

Income before income taxes

    1,565,176       1,325,344       3,044,188       2,670,462  
                                 

(Provision) for income taxes:

    (114,027 )     (60,000 )     (214,491 )     (120,006 )

Net income

    1,451,149       1,265,344       2,829,697       2,550,456  
                                 

Dividends on preferred stock

    (146,611 )     (146,611 )     (293,222 )     (293,222 )
                                 

Net income applicable to common shareholders

  $ 1,304,538     $ 1,118,733     $ 2,536,475     $ 2,257,234  
                                 

Weighted average shares, basic

    18,162,000       18,402,000       18,193,000       18,419,000  

Weighted average shares, diluted

    18,805,000       18,630,000       18,822,000       18,678,000  

Basic income per share

  $ 0.07     $ 0.06     $ 0.14     $ 0.12  

Diluted income per share

  $ 0.07     $ 0.06     $ 0.14     $ 0.12  
                                 

Comprehensive income:

                               

Net income

  $ 1,451,149     $ 1,265,344     $ 2,829,697     $ 2,550,456  

Other comprehensive loss:

                               

Unrealized loss on available-for-sale securities

    (5,904 )     -       (5,904 )     -  
                                 

Total comprehensive income

  $ 1,445,245     $ 1,265,344     $ 2,823,793     $ 2,550,456  

 

 

 

 

 

REPOSITRAK, INC.

Consolidated Condensed Statements of Cash Flows (Unaudited)

 

   

Six Months

Ended December 31,

 
   

2023

   

2022

 

Cash flows from operating activities:

               

Net income

  $ 2,829,697     $ 2,550,456  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation and amortization

    608,903       465,166  

Amortization of operating right-of-use asset

    29,838       28,450  

Stock compensation expense

    171,373       209,869  

Bad debt expense

    150,000       300,000  

(Increase) decrease in:

               

Accounts receivables

    (1,389,753 )     247,507  

Long-term receivables, prepaids and other assets

    127,755       21,431  

Increase (decrease) in:

               

Accounts payable

    (99,081 )     (300,930 )

Operating lease liability

    (28,616 )     (26,172 )

Accrued liabilities

    (71,733 )     (207,025 )

Deferred revenue

    123,564       11,240  

Net cash provided by operating activities

    2,451,947       3,299,992  
                 

Cash flows from investing activities:

               

Purchase of property and equipment

    (10,523 )     (270,854 )

Purchase of marketable securities

    (5,904 )     -  

Net cash used in investing activities

    (16,427 )     (270,854 )
                 

Cash flows from financing activities:

               

Net decrease in lines of credit

    -       (2,142,165 )

Common Stock buyback/retirement

    (1,515,574 )     (551,923 )

Redemption of series B-1 preferred

    (749,995 )     -  

Proceeds from employee stock plan

    57,743       48,903  

Dividends paid

    (840,427 )     (570,511 )

Payments on notes payable and capital leases

    (125,075 )     125,865  

Net cash used in financing activities

    (3,173,328 )     (3,089,831 )
                 

Net decrease in cash and cash equivalents

    (737,808 )     (60,693 )
                 

Cash and cash equivalents at beginning of period

    23,990,879       21,460,948  

Cash and cash equivalents at end of period

  $ 23,253,071     $ 21,400,255  
                 

Supplemental disclosure of cash flow information:

               

Cash paid for income taxes

  $ 317,944     $ 264,486  

Cash paid for interest

  $ 6,434     $ 40,446  

Cash paid for operating leases

  $ 36,282     $ 35,226  
                 

Supplemental disclosure of non-cash investing and financing activities:

               

Common stock to pay accrued liabilities

  $ 110,000     $ 152,195  

Dividends accrued on preferred stock

  $ 293,222     $ 293,222